MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial

Authors
Category Primary study
JournalMultiple sclerosis and related disorders
Year 2023
This article has no abstract
Epistemonikos ID: 1678866f3d52f128e7a42c327fd23f3692420016
First added on: Feb 15, 2024